When comparing diagnostic accuracies in distinguishing CJD from patients with non-neurodegenerative np-RPD (i.e., primarily inflammatory-related conditions and subacute dementias), CSF SNAP-25 discriminatory power exceeded that of t-tau (and the t-tau/p-tau ratio), which is currently considered the gold standard screening test in this specific clinical scenario [11, 15]. The gene discussed is MAPT; the disease is Creutzfeldt Jacob disease.